Nasdaq exas.

Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00. Exact Sciences (NASDAQ:EXAS) produces and sells diagnostic and cancer screening tests. The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Oct 8, 2023 · Exact Sciences (NASDAQ: EXAS) and Guardant Health make diagnostic tests to help screen for cancer. The two healthcare stocks have similar price-to-sales (P/S) ratios, and over the past five years ... On March 10, 2020, I opined that Exact Sciences (NASDAQ:EXAS) had solid potential but was suffering because it had announced a public offering of $850 million (upped to 1 billion) of 0.3750% ...

Enter your email address below to receive the latest news and earnings results for EXAS and its competitors with MarketBeat's FREE daily newsletter. EXAS …WebInvestors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the February 2022 expiration. One of the key inputs that goes into the price an option buyer is willing to ...MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...

The latest price target for . Exact Sciences (NASDAQ: EXAS) was reported by Goldman Sachs on Friday, November 3, 2023.The analyst firm set a price target for 90.00 …WebThe latest price target for . Exact Sciences (NASDAQ: EXAS) was reported by Goldman Sachs on November 3, 2023.The analyst firm set a price target for $90.00 expecting EXAS to rise to within 12 ...

MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS ), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473 .8 million ...Apr 26, 2021 · Exact Sciences Corporation (NASDAQ: NASDAQ:EXAS) is a leader in global cancer screening and diagnostics undergoing rapid expansion through several new add-on acquisitions. Exact Sciences (EXAS) Stock Price, News & Info | The Motley Fool Exact Sciences (NASDAQ: EXAS) $65.99 (0.9%) $0.61 Price as of November 24, 2023, 1:00 p.m. ET …WebAfter Exact Sciences (NASDAQ: EXAS) reported very favorable data on its new colon cancer screening product, investment bank Canaccord Genuity predicted that EXAS could eventually obtain at least a ...As of February 10, 2023, the average one-year price target for EXACT Sciences is $66.64. The forecasts range from a low of $35.35 to a high of $99.75. The average price target represents an ...

Nov 22, 2023 · According to the issued ratings of 16 analysts in the last year, the consensus rating for Exact Sciences stock is Moderate Buy based on the current 4 hold ratings and 12 buy ratings for EXAS. The average twelve-month price prediction for Exact Sciences is $96.56 with a high price target of $130.00 and a low price target of $73.00.

Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...

Dec 1, 2023 · On November 30, 2023, Exact Sciences Corporation (NASDAQ:EXAS) stock closed at $64.00 per share. One-month return of Exact Sciences Corporation (NASDAQ:EXAS) was -4.51%, and its shares gained 38. ... Board. Exact Sciences schedules third quarter 2023 earnings call. October 09 2023 - 06:00AM. PR Newswire (US) MADISON, Wis., Oct. 9, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a ...Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. Exact Sciences (EXAS) closed the most recent trading day at $66.08, moving -1.42% from the previous trading session. This change was narrower than the S&P 500's daily loss of 1.53%. At the same ...9 Okt 2023 ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its third quarter 2023 financial results after ...Exact Sciences' (NASDAQ:EXAS) potential is so misunderstood and undervalued that we believe that EXAS probably has an upside of 100%-300% over the next twelve months based on the prospects of its ...Among the largest underlying components of ARKG, in trading today EXACT Sciences Corp. (Symbol: EXAS) is down about 0.3%, Ionis Pharmaceuticals Inc (Symbol: IONS) is up about 3%, and Intellia ...Find the latest press releases from Exact Sciences Corporation Common Stock (EXAS) at Nasdaq.com.Oct 13, 2022 01:52PM EDT. Investors in EXACT Sciences Corp. (Symbol: EXAS) saw new options begin trading today, for the December 2nd expiration. At Stock Options Channel, our YieldBoost formula ...

Exact Sciences Corp (NASDAQ:EXAS) Intrinsic Valuation. Check if EXAS is overvalued or undervalued under the bear, base, and bull scenarios of the company's ...Shares of Exact Sciences (EXAS) have gained 22.9% over the past four weeks to close the last trading session at $43.09, but there could still be a solid upside left in the stock if short-term ...

Exact Sciences Corporation (NASDAQ:EXAS) Q3 2023 Earnings Call Transcript Operator: Good afternoon, ladies and gentlemen, and welcome to the Exact Sciences Third Quarter 2023 Earnings Conference Call.Still, here are two companies that could pull it off: Exact Sciences ( EXAS 0.37%) and Airbnb ( ABNB 1.75%). Let's consider why these two innovative businesses could turn $1,000 into $2,000 by the ...Oct 19, 2023 · "Exact Sciences Corporation (NASDAQ:EXAS) is a cancer diagnostics company whose flagship product is Cologuard, a stool-based screening test for colon cancer. The stock declined because financial ... (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced they have entered into a definitive agreement for the sale of ...Our pipeline team is responsible for advancing our future tests and developing life-changing cancer diagnostics to help patients throughout the course of their diagnosis and treatment.Exact Sciences (NASDAQ:EXAS) is a leading international company specialized in advanced cancer diagnostics. Renowned for its development of impactful cancer diagnostic tests, ...

The Investor Relations website contains information about Nasdaq, Inc.'s business for stockholders, potential investors, and financial analysts.

Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Feb 21, 2023 · Exact Sciences (EXAS) came out with a quarterly loss of $0.72 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago. These figures ... Webull offers EXAS Ent Holdg (EXAS) historical stock prices, in-depth market analysis, NASDAQ: EXAS real-time stock quote data, in-depth charts, free EXAS options chain …WebNov 20, 2023 · Kevin Conroy. https://www.exactsciences.com. Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Exact Sciences Corporation (NASDAQ:EXAS) Q2 2023 Earnings Call Transcript August 1, 2023 Exact Sciences Corporation beats earnings expectations. Reported EPS is $-0.45, expectations were $-0.51.Exact Sciences was founded in 1995 in Marlborough, Massachusetts, by Stanley Lapidus and Anthony Shuber as a company focused on the development of a non-invasive test for colorectal cancer. The company eventually went public with an initial offering on the NASDAQ in 2001. EXACT Sciences Corporation (NASDAQ:EXAS) is a leading provider of cancer screening and diagnostic tests with a focus on early detection and prevention of colorectal cancer. It launched Cologuard ...Nov 4, 2023 · Exact Sciences (NASDAQ:EXAS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 1st. The medical research company reported ($0.45) EPS for the quarter, beating ... 16 brokers have issued twelve-month price targets for Exact Sciences' stock. Their EXAS share price targets range from $73.00 to $130.00. On average, they expect the company's share price to reach $96.56 in the next year. This suggests a possible upside of 44.1% from the stock's current price. View analysts price targets for EXAS or view top ...EXAS EXAS AFTER HOURS QUOTE EXAS LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ...20.11.23 NASDAQ Composite Index-Wert EXACT Sciences-Aktie: So viel Gewinn hätte eine EXACT Sciences-Investition von vor 10 Jahren eingebracht 06.11.23 …WebExact Sciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 20th, 2024 based off last year's report dates. Learn more on EXAS's earnings history.

Exact Sciences Corporation Common Stock (EXAS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Apr 24, 2023 · Fintel reports that on May 10, 2023, Craig-Hallum upgraded their outlook for Exact Sciences (NASDAQ:EXAS) from Hold to Buy.. Analyst Price Forecast Suggests 9.61% Upside. As of April 24, 2023, the ... Exact Sciences (NASDAQ: EXAS) produces and sells diagnostic and cancer screening tests.The company is best known for its Cologuard product. That said, Exact Sciences has several other revenue ...Instagram:https://instagram. is beagle 401 k safesahara desert marathoncars . com stockvanguard balanced index funds The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure. investing in baseball cardsnvda shorts Exact Sciences (NASDAQ: EXAS) Stock Quote. Follow Insider Trades Visit website. Last Trade: US$64.00 -1.06 -1.63. Volume: 1,800,029. 5-Day Change: -1.75%. YTD ... arm stock chart The Zacks Consensus Estimate for Exact Sciences’ third-quarter 2023 revenues is pegged at $614.6 million, suggesting a rise of 17.5% from the year-ago reported figure.Fintel reports that on May 5, 2023, UBS initiated coverage of Exact Sciences (NASDAQ:EXAS) with a Neutral recommendation.. Analyst Price Forecast Suggests 18.36% Upside. As of April 24, 2023, the ...17 Nov 2023 ... PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has ...